Truist Securities has initiated coverage on Nuvalent Inc (NUVL) with a Buy rating, effective November 23, 2025. The current share price stands at $109.53. This marks Truist's first assessment of the company's investment potential based on its research into Nuvalent's business and industry dynamics.
Nuvalent Inc, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing targeted therapies for cancer. The company has a market capitalization of $7.8 billion and employs approximately 200 full-time staff. Its product candidates include Zidesamtinib (NVL-520) for ROS1-positive non-small cell lung cancer (NSCLC) and Neladalkib (NVL-655) for ALK-positive NSCLC, both designed to address resistance and minimize adverse effects.
Nuvalent's upcoming earnings reports are scheduled for February 25, 2026, with an estimated EPS of -$1.50 and revenue of $0, and May 6, 2026, also with an estimated EPS of -$1.50. The company's recent performance has shown EPS surprises, including a -21.4% surprise in Q3 2025, where the EPS was reported at -$1.70 against an estimate of -$1.40.
As of November 1, 2025, the analyst consensus for Nuvalent is categorized as Buy, with 8 Strong Buy, 13 Buy, and 1 Hold rating among 22 analysts. Analyst ratings are subject to change as new information arises, reflecting varying opinions on the company's outlook.